Emerging Therapies for Atopic Dermatitis: Jak Inhibitors

The Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) pathway is a conserved master regulator of immunity and myeloproliferation. Advanced understanding of this pathway has led to development of targeted inhibitors of Janus Kinases (Jakinibs). As a class, Jakinibs effectively treat a multitude of hematologic and inflammatory diseases. Given such success, use of Jakinibs for mitigation of atopic dermatitis is under active investigation. Herein, we review the evolving data on the safety and efficacy of Jakinibs in treatment of atopic dermatitis.